Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
$7.83
-5.7%
$8.70
$4.50
▼
$10.14
$186.42M2.32106,270 shs166,411 shs
Anthem, Inc. stock logo
ANTX
Anthem
$4.47
-1.8%
$4.58
$1.00
▼
$7.19
$168.47M-0.93254,925 shs246,857 shs
Clene Inc. stock logo
CLNN
Clene
$3.66
-6.6%
$3.89
$3.02
▼
$10.84
$57.60M1.0498,640 shs123,344 shs
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
$22.61
-2.2%
$48.07
$17.40
▼
$123.75
$221.31M-5.11281,147 shs220,514 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
-5.66%-12.02%-4.40%-8.63%+31.82%
Anthem, Inc. stock logo
ANTX
Anthem
-1.76%+11.75%+32.25%-25.13%+288.70%
Clene Inc. stock logo
CLNN
Clene
-6.63%-16.44%+18.06%-10.51%-57.04%
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-2.16%-6.22%-55.93%-73.10%-60.94%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
$7.83
-5.7%
$8.70
$4.50
▼
$10.14
$186.42M2.32106,270 shs166,411 shs
Anthem, Inc. stock logo
ANTX
Anthem
$4.47
-1.8%
$4.58
$1.00
▼
$7.19
$168.47M-0.93254,925 shs246,857 shs
Clene Inc. stock logo
CLNN
Clene
$3.66
-6.6%
$3.89
$3.02
▼
$10.84
$57.60M1.0498,640 shs123,344 shs
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
$22.61
-2.2%
$48.07
$17.40
▼
$123.75
$221.31M-5.11281,147 shs220,514 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
-5.66%-12.02%-4.40%-8.63%+31.82%
Anthem, Inc. stock logo
ANTX
Anthem
-1.76%+11.75%+32.25%-25.13%+288.70%
Clene Inc. stock logo
CLNN
Clene
-6.63%-16.44%+18.06%-10.51%-57.04%
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-2.16%-6.22%-55.93%-73.10%-60.94%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
3.00
Buy$18.20132.44% Upside
Anthem, Inc. stock logo
ANTX
Anthem
2.33
Hold$9.00101.34% Upside
Clene Inc. stock logo
CLNN
Clene
2.71
Moderate Buy$34.00828.96% Upside
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
2.92
Moderate Buy$126.29458.54% Upside

Current Analyst Ratings Breakdown

Latest CLNN, ACOG, DRUG, and ANTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/12/2026
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
Set Price TargetOutperform$21.00
11/11/2026
Clene Inc. stock logo
CLNN
Clene
UpgradeSell (E+) ➝ Sell (D-)
11/3/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Lower Price TargetOutperform$126.00 ➝ $107.00
11/2/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Reiterated RatingBuy$147.00 ➝ $37.00
11/2/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Reiterated RatingBuy
10/27/2026
Clene Inc. stock logo
CLNN
Clene
DowngradeSell (D-) ➝ Sell (E+)
10/19/2026
Clene Inc. stock logo
CLNN
Clene
Reiterated RatingBuy
10/15/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Initiated CoverageOutperform$150.00
10/9/2026
Clene Inc. stock logo
CLNN
Clene
UpgradeSell (E+) ➝ Sell (D-)
10/2/2026
Anthem, Inc. stock logo
ANTX
Anthem
Reiterated RatingSell (D-)
9/28/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
UpgradeStrong-Buy
(Data available from 11/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
$10.22M16.69N/AN/A$2.88 per share2.72
Anthem, Inc. stock logo
ANTX
Anthem
N/AN/AN/AN/A$1.99 per shareN/A
Clene Inc. stock logo
CLNN
Clene
$200K263.52N/AN/A($1.03) per share-3.55
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/AN/AN/AN/A$8.33 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
-$20.67M-$1.37N/AN/AN/A-147.26%-50.90%-41.23%N/A
Anthem, Inc. stock logo
ANTX
Anthem
-$35.17M-$0.93N/AN/AN/AN/A-48.74%-44.56%N/A
Clene Inc. stock logo
CLNN
Clene
-$26.17M-$2.60N/AN/AN/A-11,274.79%N/A-77.56%N/A
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-$8.74M-$2.08N/AN/AN/AN/A-12.46%-12.30%12/22/2026 (Estimated)

Latest CLNN, ACOG, DRUG, and ANTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/11/2026Q3 2026
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
-$0.3350-$0.35-$0.0150-$0.35$7.04 million$7.78 million
11/9/2026Q3 2026
Anthem, Inc. stock logo
ANTX
Anthem
N/A-$0.17N/A-$0.17N/AN/A
11/4/2026Q3 2026
Clene Inc. stock logo
CLNN
Clene
-$0.4540$0.05+$0.5040$0.05$0.07 million$0.06 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/AN/AN/AN/AN/A
Anthem, Inc. stock logo
ANTX
Anthem
N/AN/AN/AN/AN/A
Clene Inc. stock logo
CLNN
Clene
N/AN/AN/AN/AN/A
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/A
9.03
8.04
Anthem, Inc. stock logo
ANTX
Anthem
N/A
10.48
14.32
Clene Inc. stock logo
CLNN
Clene
N/A
0.85
0.84
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/A
122.00
122.00

Institutional Ownership

CompanyInstitutional Ownership
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/A
Anthem, Inc. stock logo
ANTX
Anthem
90.47%
Clene Inc. stock logo
CLNN
Clene
23.28%
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
40.52%

Insider Ownership

CompanyInsider Ownership
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
8.60%
Anthem, Inc. stock logo
ANTX
Anthem
22.61%
Clene Inc. stock logo
CLNN
Clene
28.30%
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
42.66%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
7121.78 million19.91 millionOptionable
Anthem, Inc. stock logo
ANTX
Anthem
N/A37.94 million29.37 millionOptionable
Clene Inc. stock logo
CLNN
Clene
7914.40 million10.33 millionOptionable
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
259.73 million5.58 millionOptionable

Recent News About These Companies

Bright Minds stock plunges as FDA halts epilepsy trial

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alpha Cognition stock logo

Alpha Cognition NASDAQ:ACOG

$7.83 -0.47 (-5.66%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$7.86 +0.03 (+0.32%)
As of 11/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Anthem stock logo

Anthem NASDAQ:ANTX

$4.47 -0.08 (-1.76%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$4.47 0.00 (0.00%)
As of 11/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Clene stock logo

Clene NASDAQ:CLNN

$3.66 -0.26 (-6.63%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$3.76 +0.10 (+2.73%)
As of 11/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Bright Minds Biosciences stock logo

Bright Minds Biosciences NASDAQ:DRUG

$22.61 -0.50 (-2.16%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$22.35 -0.26 (-1.16%)
As of 11/16/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.